Fact CheckerSign in

NCT07779226Not yet recruiting

DecNef for Auditory Verbal Hallucinations (AVH) in Schizophrenia

Decoded fMRI Neurofeedback for Auditory Verbal Hallucinations in Schizophrenia

Source: ClinicalTrials.gov · Last updated 14 Oct 2026

Brief summary (registry, in English)

The purpose of this study is to learn whether a research neurofeedback training approach done during MRI scans may help reduce hallucinations such as the experience of hearing voices persistent despite treatment.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
51 (estimated)
First submitted
19 Aug 2026
Start date
1 Dec 2026
Primary completion date
1 Jan 2028
Lead sponsor
Columbia University
NCT number
NCT07779226

What you commit to

  • Study type: Interventional
  • Planned participants: 51
  • From 1 Dec 2026 to the primary completion date, 1 Jan 2028
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Diagnosis of moderate or severe substance use disorder (excluding nicotine) within the previous 90 days
  • Participation in study of investigational medication/device within the past 4 weeks
  • Contraindication to MRI scanning, including metal implants or clinically meaningful claustrophobia
  • Participants with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 3 months prior to screening or participants who represent a significant risk of suicide or violence in the opinion of the investigator.

Other illness

  • Any clinically significant or unstable medical illness, condition, or disorder that is anticipated to potentially compromise participant safety during study, including history of seizure, epilepsy in self or first degree relatives, stroke, brain surgery, head injury with loss of consciousness \> 1 hour or clear cognitive sequelae, intracranial metal implants, known structural brain lesions.
  • History of significant violent behavior in the past 3 months, posing a risk of homicide or having symptoms that would be exacerbated by study participation or travel to the site in the opinion of the investigator.

Other

  • Positive toxicology screen for any substances of abuse
  • Pregnant persons. Persons of child-bearing potential must have a negative urine β-hCG pregnancy test at Visit 1 and Visit 1a (if applicable)

Who the study is looking for

  • Individuals aged 18 to 55, inclusive at screen
  • Capable of understanding the study procedures and willing and able to provide informed consent
  • Diagnosed with schizophrenia or schizoaffective disorder
  • Taking an antipsychotic medication at a stable dose for at least 4 weeks. All oral and depot antipsychotics are allowable.
  • Mean Auditory Hallucination Rating Scale (AHRS) score \>2 (moderate) and AHRS Frequency ≥ 4 (hourly AVH: Frequent at least 3 to 6 per hour).
  • Meeting the decoder performance criterion, operationalized as ≥ 55% decoding accuracy. Baseline MRI may be repeated once for subthreshold decoder-accuracy at the discretion of the PIs.
  • Normal hearing, operationalized as normal conversational hearing.
  • Willing to use qualified methods of contraception (listed in section 5.3) for the study duration (for persons of childbearing potential only, unless post-menopausal or surgically sterile).

Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
New York State Psychiatric Institute
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status
Columbia University Irving Medical Center
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.